Emiko Tsuda

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Health‐related quality‐of‐life and treatment targets in myasthenia gravis

Kimiaki Utsugisawa, Shigeaki Suzuki, Yuriko Nagane et al. · Muscle & Nerve · 2014 · 97 citations

Pharmacy, Neurology, Pharmacotherapy +13

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Early fast‐acting treatment strategy against generalized myasthenia gravis

Kimiaki Utsugisawa, Yuriko Nagane, Tetsuya Akaishi et al. · Muscle & Nerve · 2016 · 75 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +7

Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study

Yuriko Nagane, Hiroyuki Murai, Tomihiro Imai et al. · BMJ Open · 2017 · 70 citations · Full text

Medicine, Neurology, Pharmacotherapy +12